Fact or fiction - Identifying the elusive multiple myeloma stem cell

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Kellner, Joshua ^a,b   Liu, Bei ^a,b   Kang, Yubin ^a,b   Li, Zihai ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CD19 ANTIGEN; CD27 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CELL SURFACE MARKER; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; PREDNISONE; SYNDECAN 1;

B LYMPHOCYTE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL POPULATION; CELL RENEWAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; MEMORY CELL; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER T CELL; NONHUMAN; PLASMA CELL; RECURRENT DISEASE; REVIEW; STEM CELL; SUPPRESSOR CELL; SYSTEMATIC REVIEW; T LYMPHOCYTE; THERAPY RESISTANCE; WNT SIGNALING PATHWAY;

ANIMALS; DISEASE PROGRESSION; HUMANS; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS;

EID: 84889051762     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-91     Document Type: Review

References (116)

1. Growth characteristics of a mouse plasma cell tumor. Bergsagel DE, Valeriote FA, Cancer Res 1968 28 11 2187 2196
2. Mouse myeloma tumor stem cells: a primary cell culture assay. Park CH, Bergsagel DE, McCulloch EA, J Natl Cancer Inst 1971 46 2 411 422
3. Primary bioassay of human tumor stem cells. Hamburger AW, Salmon SE, Science 1977 197 4302 461 463
4. Primary bioassay of human myeloma stem cells. Hamburger A, Salmon SE, J Clin Invest 1977 60 4 846 854 (Pubitemid 8208477)
5. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Bonnet D, Dick JE, Nat Med 1997 3 7 730 737 (Pubitemid 27298715)
6. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 1 10 29
7. Pathogenesis of myeloma. Anderson KC, Carrasco RD, Annu Rev Pathol 2011 6 249 274
8. Understanding the molecular biology of myeloma and its therapeutic implications. Boyd KD, et al. Expert Rev Hematol 2012 5 6 603 617
9. Latest advances and current challenges in the treatment of multiple myeloma. Mahindra A, et al. Nat Rev Clin Oncol 2012 9 3 135 143
10. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Bakkus MH, et al. Blood 1992 80 9 2326 2335
11. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Bakkus MH, et al. Br J Haematol 1994 87 1 68 74 (Pubitemid 24207001)
12. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Bergsagel PL, et al. Blood 1995 85 2 436 447
13. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Billadeau D, et al. J Exp Med 1993 178 3 1023 1031 (Pubitemid 23260440)
14. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Pilarski LM, et al. Clin Cancer Res 2000 6 2 585 596 (Pubitemid 30111483)
15. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Szczepek AJ, et al. Blood 1998 92 8 2844 2855 (Pubitemid 28469098)
16. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. Bergui L, et al. J Exp Med 1989 170 2 613 618 (Pubitemid 19204289)
17. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. Vescio RA, et al. J Immunol 1995 155 5 2487 2497
18. In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Rasmussen T, et al. Leuk Lymphoma 2004 45 7 1413 1417 (Pubitemid 38701919)
19. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Yaccoby S, Barlogie B, Epstein J, Blood 1998 92 8 2908 2913 (Pubitemid 28469106)
20. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Yaccoby S, Epstein J, Blood 1999 94 10 3576 3582 (Pubitemid 29536154)
21. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Kim D, et al. Leukemia 2012 26 12 2530 2537
22. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Pilarski LM, et al. Blood 2000 95 3 1056 1065 (Pubitemid 30062731)
23. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Pilarski LM, et al. Exp Hematol 2002 30 3 221 228 (Pubitemid 34203728)
24. Characterization of clonogenic multiple myeloma cells. Matsui W, et al. Blood 2004 103 6 2332 2336 (Pubitemid 38326254)
25. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Matsui W, et al. Cancer Res 2008 68 1 190 197 (Pubitemid 351380120)
26. Clonogenic multiple myeloma cells have shared stemness signature assocuated with patient survival. Reghunathan R, et al. Oncotarget 2013 4 8 1230 1240
27. The Hedgehog and Wnt signalling pathways in cancer. Taipale J, Beachy PA, Nature 2001 411 6835 349 354 (Pubitemid 32467044)
28. Gli and hedgehog in cancer: tumours, embryos and stem cells. Ruizi Altaba AP, Sanchez N, Dahmane, Nat Rev Cancer 2002 2 5 361 372 (Pubitemid 37328949)
29. Emerging role of Notch in stem cells and cancer. Wang Z, et al. Cancer Lett 2009 279 1 8 12
30. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Takebe N, et al. Nat Rev Clin Oncol 2011 8 2 97 106
31. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Peacock CD, et al. Proc Natl Acad Sci U S A 2007 104 10 4048 4053 (Pubitemid 47181576)
32. Hedgehog signaling in animal development: paradigms and principles. Ingham PW, McMahon AP, Genes Dev 2001 15 23 3059 3087 (Pubitemid 33115673)
33. Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Vestergaard J, et al. Lung Cancer 2006 52 3 281 290 (Pubitemid 43674545)
34. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mimeault M, et al. Mol Cancer Ther 2010 9 3 617 630
35. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. Von Hoff DD, et al. N Engl J Med 2009 361 12 1164 1172
36. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. Rudin CM, et al. N Engl J Med 2009 361 12 1173 1178
37. Proximal events in Wnt signal transduction. Angers S, Moon RT, Nat Rev Mol Cell Biol 2009 10 7 468 477
38. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Grigoryan T, et al. Genes Dev 2008 22 17 2308 2341
39. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Derksen PW, et al. Proc Natl Acad Sci U S A 2004 101 16 6122 6127 (Pubitemid 38520538)
40. Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32). Bueno C, Lopes LF, Menendez P, Blood Cells Mol Dis 2007 39 3 366 368 (Pubitemid 47484466)
41. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Chim CS, et al. Leukemia 2007 21 12 2527 2536 (Pubitemid 350148897)
42. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Dutta-Simmons J, et al. Blood 2009 114 13 2699 2708
43. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Qiang YW, et al. Br J Haematol 2010 148 5 726 738
44. AV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Yao H, et al. Blood Cancer J 2011 1 11 43
45. Antagonistic effect of small-molecule inhibitors of Wnt/beta-catenin in multiple myeloma. Narayanan BA, et al. Anticancer Res 2012 32 11 4697 4707
46. Unfolded protein response in cancer: the Physician's perspective. Li X, Zhang K, Li Z, J Hematol Oncol 2011 4 1 8
47. Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Liu B, et al. Proc Natl Acad Sci U S A 2013 110 17 6877 6882
48. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Hua Y, et al. Clin Cancer Res 2013 19 22 6242 6251
49. Notch signaling: cell fate control and signal integration in development. Artavanis-Tsakonas S, Rand MD, Lake RJ, Science 1999 284 5415 770 776 (Pubitemid 29291335)
50. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Hassan KA, et al. Clin Cancer Res 2013 19 8 1972 1980
51. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. Won HY, et al. FASEB J 2012 26 12 5002 5013
52. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Bao B, et al. Cancer Lett 2011 307 1 26 36
53. Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway. Garcia Campelo MR, et al. Clin Transl Oncol 2011 13 2 77 83
54. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Hovinga KE, et al. Stem Cells 2010 28 6 1019 1029
55. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Chiron D, et al. Blood Cells Mol Dis 2012 48 4 247 253
56. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Xu D, et al. Leukemia 2012 26 6 1402 1405
57. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Jundt F, et al. Blood 2004 103 9 3511 3515 (Pubitemid 38525685)
58. Stemness of B-cell progenitors in multiple myeloma bone marrow. Boucher K, et al. Clin Cancer Res 2012 18 22 6155 6168
59. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Nefedova Y, et al. Blood 2008 111 4 2220 2229 (Pubitemid 351451536)
60. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Schwarzer R, et al. Leukemia 2008 22 12 2273 2277
61. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Mirandola L, et al. Leukemia 2013 27 7 1558 1566
62. Urethane in the treatment of multiple myeloma. Weder C, Can Med Assoc J 1950 62 6 589 590
63. Melphalan in multiple myeloma. Hoogstraten B, et al. Blood 1967 30 1 74 83
64. Multiple myeloma. Ii. Analysis of cyclophosphamide therapy in 165 patients. Korst DR, et al. JAMA 1964 189 758 762
65. Treatment for multiple myeloma. Combination chemother with different melphalan dose regimens. Alexanian R, et al. JAMA 1969 208 9 1680 1685
66. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. Cooper MR, et al. J Clin Oncol 1986 4 9 1331 1339 (Pubitemid 16028027)
67. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Blade J, et al. Hematol J 2001 2 4 272 278 (Pubitemid 32771602)
68. Antitumor activity of thalidomide in refractory multiple myeloma. Singhal S, et al. N Engl J Med 1999 341 21 1565 1571
69. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Dimopoulos M, et al. N Engl J Med 2007 357 21 2123 2132 (Pubitemid 350146107)
70. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. Usmani SZ, et al. J Hematol Oncol 2010 3 1 40
71. Ibrutinib and novel BTK inhibitors in clinical development. Akinleye A, et al. J Hematol Oncol 2013 6 59
72. Novel immunomodulatory compounds in multiple myeloma. Saini N, Mahindra A, Expert Opin Investig Drugs 2013 22 2 207 215
73. Thalidomide and its analogues in the treatment of multiple myeloma. Latif T, et al. Exp Hematol Oncol 2012 1 1 27
74. The cancer stem cell: premises, promises and challenges. Clevers H, Nat Med 2011 17 3 313 319
75. Stromal niches, plasma cell differentiation and survival. Moser K, et al. Curr Opin Immunol 2006 18 3 265 270
76. Organization of immunological memory by bone marrow stroma. Tokoyoda K, et al. Nat Rev Immunol 2010 10 3 193 200
77. Flexible and dynamic organization of bone marrow stromal compartment. Anjos-Afonso F, Bonnet D, Br J Haematol 2007 139 3 373 384 (Pubitemid 47512189)
78. Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. Nilsson SK, et al. J Histochem Cytochem 1998 46 3 371 377 (Pubitemid 28117387)
79. Insulin-like growth factor-1 acts as a chemoattractant factor for 5 T2 multiple myeloma cells. Vanderkerken K, et al. Blood 1999 93 1 235 241 (Pubitemid 29019408)
80. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Podar K, et al. Blood 2001 98 2 428 435
81. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Mitsiades CS, et al. Cancer Cell 2004 5 3 221 230 (Pubitemid 38402114)
82. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Chauhan D, et al. Blood 1996 87 3 1104 1112 (Pubitemid 26043538)
83. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Moreaux J, et al. Blood 2004 103 8 3148 3157 (Pubitemid 38451693)
84. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Dankbar B, et al. Blood 2000 95 8 2630 2636 (Pubitemid 30210543)
85. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Hideshima T, et al. Oncogene 2001 20 33 4519 4527 (Pubitemid 32772434)
86. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Gupta D, et al. Leukemia 2001 15 12 1950 1961 (Pubitemid 33115003)
87. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. Roodman GD, et al. J Clin Invest 1992 89 1 46 52
88. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Barille S, et al. Blood 1995 86 8 3151 3159
89. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Shipman CM, Croucher PI, Cancer Res 2003 63 5 912 916 (Pubitemid 36278418)
90. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Bataille R, et al. J Clin Oncol 1989 7 12 1909 1914 (Pubitemid 20014340)
91. Pathogenesis of myeloma bone disease. Roodman GD, Leukemia 2009 23 3 435 441
92. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Ehrlich LA, Roodman GD, Immunol Rev 2005 208 252 266 (Pubitemid 41746397)
93. Integrins in cancer: biological implications and therapeutic opportunities. Desgrosellier JS, Cheresh DA, Nat Rev Cancer 2010 10 1 9 22
94. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Pellat-Deceunynck C, et al. Cancer Res 1995 55 16 3647 3653
95. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Damiano JS, et al. Blood 1999 93 5 1658 1667 (Pubitemid 29102494)
96. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Westhoff MA, et al. Oncogene 2008 27 39 5169 5181
97. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Matsunaga T, et al. Leukemia 2008 22 2 353 360 (Pubitemid 351250540)
98. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Alsayed Y, et al. Blood 2007 109 7 2708 2717 (Pubitemid 46482062)
99. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Lapidot T, Ann N Y Acad Sci 2001 938 83 95 (Pubitemid 32620021)
100. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Miyamoto T, Weissman IL, Akashi K, Proc Natl Acad Sci U S A 2000 97 13 7521 7526 (Pubitemid 30431496)
101. Circulating tumor cells in patients with breast cancer dormancy. Meng S, et al. Clin Cancer Res 2004 10 24 8152 8162 (Pubitemid 40053373)
102. The CML stem cell: evolution of the progenitor. Stuart SA, Minami Y, Wang JY, Cell Cycle 2009 8 9 1338 1343
103. A new murine aggressive leukemic model. Vereecque R, et al. Leuk Res 1999 23 4 415 416 (Pubitemid 29166777)
104. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Vereecque R, et al. Gene Ther 2000 7 15 1312 1316 (Pubitemid 30623778)
105. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Saudemont A, Quesnel B, Blood 2004 104 7 2124 2133 (Pubitemid 39297867)
106. Cancer immunotherapy comes of age. Mellman I, Coukos G, Dranoff G, Nature 2011 480 7378 480 489
107. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Tirapu I, et al. Cancer Res 2006 66 4 2442 2450
108. Immunodeficiency and immunotherapy in multiple myeloma. Pratt G, Goodyear O, Moss P, Br J Haematol 2007 138 5 563 579 (Pubitemid 47208476)
109. Dysfunctional T regulatory cells in multiple myeloma. Prabhala RH, et al. Blood 2006 107 1 301 304 (Pubitemid 43053555)
110. In vivo peripheral expansion of naive CD4 + CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Beyer M, et al. Blood 2006 107 10 3940 3949 (Pubitemid 43726800)
111. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. Muthu Raja KR, et al. PLoS One 2012 7 10 47077
112. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Dhodapkar KM, et al. Blood 2008 112 7 2878 2885
113. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Prabhala RH, et al. Blood 2010 115 26 5385 5392
114. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Gorgun GT, et al. Blood 2013 121 15 2975 2987
115. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Carbone E, et al. Blood 2005 105 1 251 258 (Pubitemid 40053090)
116. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. Dhodapkar MV, et al. J Exp Med 2003 197 12 1667 1676 (Pubitemid 36745342)